Chlorthalidone

Generic Name: Chlorthalidone

Brand Names: Edarbyclor, Tenoretic, Thalitone

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₁ClN_₂O_₄S

CAS Number: 77-36-1

Unique Ingredient Identifier: Q0MQD1073Q

Background: Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in t...

Indication: Chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.

Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy....

Associated Conditions: Calcium Nephrolithiasis, Edema, Hypertension

Associated Therapies: -

Clinical Trials

Skin Sodium and Salt Sensitivity of Blood Pressure

Not Applicable

Not yet recruiting

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: Chlortalidone

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 60

Registration Number: NCT05976438

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧
St Thomas' Hospital, London, United Kingdom

Diuretic Use in Hemodialysis Patients With Residual Renal Function

Phase 4

Suspended

Conditions: End Stage Renal Disease on Dialysis

Interventions: Drug: Furosemide
Drug: Chlorthalidone

First Posted Date: 2023-06-22

Last Posted Date: 2024-03-05

Lead Sponsor: University of Alberta

Target Recruit Count: 34

Registration Number: NCT05915286

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Phase 4

Recruiting

Conditions: Hypertension
Left Ventricular Hypertrophy

Interventions: Drug: Eplerenone
Drug: Chlorthalidone
Drug: Potassium

First Posted Date: 2022-10-25

Last Posted Date: 2024-12-16

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 75

Registration Number: NCT05593055

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

Phase 4

Withdrawn

Conditions: High Blood Pressure
Liver Transplant
Renal Function Abnormal

Interventions: Drug: Amlodipine Besylate
Drug: Chlorthalidone

First Posted Date: 2022-03-11

Last Posted Date: 2023-10-13

Lead Sponsor: Northwestern University

Registration Number: NCT05275907

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

Phase 2

Recruiting

Conditions: Renal Insufficiency
Chronic Hypertension

Interventions: Drug: Spironolactone
Drug: Placebo
Drug: Chlorthalidone

First Posted Date: 2022-02-03

Last Posted Date: 2023-08-14

Lead Sponsor: Indiana Institute for Medical Research

Target Recruit Count: 24

Registration Number: NCT05222191

Locations: 🇺🇸
Richard L Roudebush VA Medical Center, Indianapolis, Indiana, United States

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Danazol
Drug: Testosterone cyclopentylpropionate
Drug: Bupropion
Drug: Anastrozole
Drug: Chlorthalidone

First Posted Date: 2021-02-17

Last Posted Date: 2021-04-26

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 9

Registration Number: NCT04757532

Locations: 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

Phase 2

Completed

Conditions: Cardiorenal Syndrome

Interventions: Drug: Furosemide intravenous solution
Drug: Chlortalidone
Drug: Spironolactone

First Posted Date: 2020-05-19

Last Posted Date: 2020-09-14

Lead Sponsor: Hospital Civil de Guadalajara

Target Recruit Count: 80

Registration Number: NCT04393493

Locations: 🇲🇽
HCG, Guadalajara, Jalisco, Mexico
🇲🇽
Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico

Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

Phase 2

Completed

Conditions: Renal Insufficiency, Chronic

Interventions: Drug: Chlorthalidone
Drug: Bumetanide

First Posted Date: 2019-04-23

Last Posted Date: 2020-11-23

Lead Sponsor: Hospital General de México Dr. Eduardo Liceaga

Target Recruit Count: 34

Registration Number: NCT03923933

Locations: 🇲🇽
Hospital General de Mexico, Mexico City, Mexico

Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs

Not Applicable

Completed

Conditions: Ambulatory Blood Pressure Monitoring
Arterial Stiffness

Interventions: Drug: Olmesartan
Drug: Chlorthalidone

First Posted Date: 2018-06-18

Last Posted Date: 2018-06-18

Lead Sponsor: AHEPA University Hospital

Target Recruit Count: 60

Registration Number: NCT03560804

Locations: 🇬🇷
Hypertension Excellence Center, AHEPA University Hospital, Thessaloniki, Greece

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

Phase 2

Terminated

Conditions: Type 1 Diabetes Mellitus
Hypercalciuria

Interventions: Drug: Chlorthalidone

First Posted Date: 2017-10-30

Last Posted Date: 2021-01-05

Lead Sponsor: University of Rochester

Target Recruit Count: 1

Registration Number: NCT03325114

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy